Clinical and epidemiologic characteristics of patients with pulmonary arterial hypertension (PAH) and controls.
| Healthy Controls | Idiopathic PAH | Scleroderma-PAH | Scleroderma-only Control | p (for patient groups) | |
|---|---|---|---|---|---|
| Characteristics | |||||
| No. | 13 | 28 | 10 | 8 | |
| M:F | 2:11 | 8:20 | 2:8 | 1:7 | 0.743 |
| Age, yrs | 46.0 ± 14.1 | 51.9 ± 13.6 | 54.3 ± 14.2 | 58.5 ± 12.1 | 0.632 |
| BMI, k/gm2 | 24.3 ± 3.6 | 26.3 ± 6.7 | 23.7 ± 4.5 | 25.9 ± 4.1 | 0.259 |
| NYHA | 1.0 | 1.9 ± 0.7** | 2.2 ± 0.6** | 1.0 | 0.184 |
| I, n (%) | 13 | 7 (24) | 1 (10) | 8 | |
| II, n (%) | 17 (61) | 6 (61) | |||
| III-IV, n (%) | 4 (14) | 3 (30) | |||
| Clinical findings | |||||
| Pulse/min | 73.5 ± 10.6 | 78.2 ± 12.0 | 81.2 ± 12.6 | 83.2 ± 7.8* | 0.509 |
| BL sat, % | 97.5 ± 1.4 | 94.3 ± 5.1* | 94.2 ± 5.5* | 98.3 ± 2.7 | 0.964 |
| 6MWT, m | 512 ± 35 | 399 ± 118 | 315 ± 77** | 451 ± 53 | 0.044 |
| 6MWT sat, % | 98.3 ± 0.8 | 89.8 + 9.1** | 85.0 ± 12.8** | 97.8 ± 2.1 | 0.208 |
| DLCO, % | 98.5 ± 3.5 | 58.1 ± 20.3** | 43.0 ± 28.1** | 74.0 ± 28.8 | 0.079 |
| PPR, mm Hg | 23.0 ± 4.2 | 70.5 ± 21.6** | 69.3 ± 20.1** | 31.2 ± 11.2 | 0.882 |
| CO, l/min | 4.3 ± 1.4 | 4.4 ± 1.5 | 5.9 ± 2.3 | 0.884 | |
| PVR, MPa•s/m3 | 11.4 ± 5.6 | 14.9 ± 5.7 | 2.8 ± 0.7 | 0.209 | |
| PAT ratio | 2.20 ± 0.25 | 1.84 ± 0.51* | 1.66 ± 0.66* | 2.03 ± 0.38 | 0.380 |
| Al, % | 10.5 ± 19.6 | 9.0 ± 21.5 | 20.1 ± 19.1 | 24.4 ± 18.9 | 0.199 |
↵* p < 0.05 compared to control;
↵** p < 0.01 compared to control. BMI: body mass index; NYHA: NewYork Heart Association; BL sat: baseline oxygen saturation; PPR: mean pulmonary pressure; CO: cardiac outpatient. DLCO: carbon monoxide diffusion capacity; PVR: pulmonary vascular resistance in pascal seconds/m3; 6MWT: 6-minute walk test; PAT: peripheral arterial tone; AI: augmentation index.